華益藥業(yè)科技（安徽）有限公司是一家通過Eu GMP，同時(shí)擁有合作緊密的一致性評價(jià)中心和生物等效性實(shí)驗(yàn)室，可以提供從立項(xiàng)、處方/工藝/檢驗(yàn)方法開發(fā)、驗(yàn)證、注冊到商業(yè)化生產(chǎn)的高質(zhì)高效的一站式服務(wù)。 公司現(xiàn)計(jì)劃進(jìn)入國內(nèi)市場，誠尋有市場前景的產(chǎn)品，歡迎原料藥廠、研發(fā)企業(yè)或銷售企業(yè)洽談合作，合作方式包括全產(chǎn)權(quán)轉(zhuǎn)讓（MAH）、聯(lián)合投資、技術(shù)轉(zhuǎn)讓、委托研發(fā)和生產(chǎn)等各種模式，有興趣的同行皆可談。聯(lián)系人：周15056092160（同微信）   [更多]

標(biāo)題： 1、January 8, 1982 Cough Variant Asthma in Children Paul J. Hannaway, MD; G. David K. Hopper, MD JAMA. 1982;247(2):206-208. doi:10.1001/jama.1982.03320270044023 2、J Dig Dis. 2018 Feb 1. doi: 10.1111/1751-2980.12583. [Epub ahead of print] Tolvaptan in Chinese cirrhotic patients with ascites: A randomized, placebo-controlled phase 2 trial. 3、Brexit from current guideline recommendations 4、Tolvaptan in Chinese cirrhotic patients with ascites: a randomized, placebo-controlled phase 2 trial 5、Increased serum c-reactive protein and decreased urinary aquaporin 2 levels are predictive of the efficacy of tovaptan in patients with liver cirrhosis 6、In vitro p-glycoproten interactions and steady-state pharmacokinetic interactions between tolvaptan and digoxin in healthy subjects. 7、Pharmacokinetics and pharmacodynamics interaction between tolvaptan and warfarin in healthy subjects 8、Absolute bioavailability of tolvaptan and determination of minimally effective concentrations in healthy subjects 9、7-chloro-5-hydroxy-1-[2-methyl-4-(2-methylbenzoy-amino)benzoy]-2,3,4,5-tetrahydro-1H-1-benzazepine(OPC-41061): a potent, orally active nonpeptide arginine vasorpressin V2 receptor antagonist 10:33:17   [更多]

《預(yù)沖式?jīng)_管注射器》信息   [更多]

求鹽酸土霉素BP2017一份   [更多]

某中藥廠現(xiàn)有一類新藥證書、國藥準(zhǔn)字批號、《國家重點(diǎn)馴養(yǎng)繁殖許可證》，屬高效益稀缺資源。因GMP車間改造，現(xiàn)急需資金七百萬，有意者可通過股權(quán)融資參與經(jīng)營或股權(quán)轉(zhuǎn)讓。歡迎垂詢I86 I932 I63I。   [更多]

藥智網(wǎng)建有一個(gè)中標(biāo)數(shù)據(jù)庫http://db.yaozh.com/yaopinzhongbiao.html收集了全國各省市的藥品中標(biāo)信息，為了保證給大家有更準(zhǔn)確及時(shí)的信息，需要對藥品中標(biāo)信息數(shù)據(jù)庫及時(shí)更新，現(xiàn)請人進(jìn)行最新中標(biāo)數(shù)據(jù)的收集整理。 工作內(nèi)容：及時(shí)查到最新公布的藥品中標(biāo)信息，并將最新的文件按指定要求處理成規(guī)范的格式(excel表)。交稿如發(fā)現(xiàn)遺漏，反饋后望及時(shí)補(bǔ)充。 不是一次性任務(wù)。長期合作(一年以上)   [更多]

標(biāo)題： 1、PMID：29241352 Rhabdomyolysis and elevated liver enzymes after rapid correction of hyponatremia due to pneumonia and concurrent use of aripiprazole: a case report 2、PMID：18306096 Hyponatremia in psychiatric patients: update on evaluation and management 3、PMID：20643634 The assessment and treatment of water imbalance in patients with psychosis 4、Marí M, Morales A, Colell A, García-Ruiz C, Fernández-Checa JC. Mitochondrial glutathione, a key survival anti-oxidant. Antioxid Redox Signal. (2009) 11(11)2685-700 5、Yeni D;Effect of α-lipoic acid on sperm quality, reproductive tract measures in thinner exposed rats. 6、PRELIMINARY BASELINE DATA OF HYPERTENSIVE PATIENTS INCLUDED IN THE CATCH (CANDESARTAN ASSESSMENT IN THE TREATMENT OF CARDIAC HYPERTROPHY) STUDY: P1.195 7、Synthesis and antibacterial activity of 1-cyclopropyl-6,8-difluoro-7-(2-substituted 4,6-dihydro-1H-pyrrolo[3,4-d]thiazol-5-yl)-1,4-dihydro-4-oxoquinoline-3-carb oxylic acid 8、Steady-state pharmacokinetics of tenofovir disoproxil fumarate in human immunodeficiency virus-infected Chinese patients: Expert Review of Clinical Pharmacology: Vol 10, No 7 9、Bioequivalence study of two oral tablet formulations containing tenofovir disoproxil fumarate in healthy volunteers. - PubMed - NCBI 10、 Huiming Ma.Protective function of alpha-lipoic acid on sperm motility and mitochondrial function during goat sperm-mediated gene transfer[J].Small Ruminant Research 99 (2011) 191-198 11、The safety of medical devices containing DEHP plasticized PVC or other plasticizers on neonates and other groups possibly at risk (2015 update). 12、Mechanisms of recognition of amyloid-β (Aβ) monomer, oligomer, and fibril by homologous antibodies. 將符合標(biāo)題的文獻(xiàn)PDF格式上傳，按照交稿時(shí)間的先后確認(rèn)稿件，先到先得   [更多]

天晴，潤眾制藥甲磺酸伊馬替尼原料藥標(biāo)準(zhǔn)！   [更多]

標(biāo)題：1000元懸賞提取國外上市醫(yī)藥企業(yè)年報(bào)中產(chǎn)品銷售數(shù)據(jù) 需求名稱：年報(bào)數(shù)據(jù)處理 價(jià)格預(yù)算：200元/人 詳細(xì)要求： ① 從任務(wù)主手中獲取指定企業(yè)的年報(bào)文件， ② 將年報(bào)中的相應(yīng)數(shù)據(jù)填入相應(yīng)表格，年報(bào)中沒有的數(shù)據(jù)表格相應(yīng)內(nèi)容不做填寫， ③ 要求仔細(xì)認(rèn)真，熟悉英文或?qū)Ψg工具的熟練使用， ④ 價(jià)格5元/個(gè)（填寫完了審核通過，每個(gè)年報(bào)要求把所有產(chǎn)品銷售額收集填寫完）， ⑤ 如若審核發(fā)現(xiàn)有填錯(cuò)，填漏；以每填錯(cuò)，填漏一個(gè)數(shù)據(jù)1元計(jì)量扣除賞金。 交稿方式：請將數(shù)據(jù)表格直接打包在藥智網(wǎng)交稿就可以了 交稿時(shí)間：可與任務(wù)主協(xié)商實(shí)際交稿時(shí)間。   [更多]

三門峽康瑞藥業(yè)有限公司注冊地址：河南三門峽產(chǎn)業(yè)聚集區(qū)；經(jīng)營范圍：藥用果膠及果膠鉍生產(chǎn)與銷售；藥品生產(chǎn)手續(xù)齊全，尋求入股合作，建設(shè)廠房和購進(jìn)設(shè)備；或公司整套手續(xù)轉(zhuǎn)讓。   [更多]